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a b s t r a c t
Epigenetic alterations of human papillomavirus (HPV) genome play an important role in virus life cycle
and carcinogenic progression. The aim of the current study was to investigate the correlation between
the grade of cervical pathology and DNA methylation status within the L1 gene and the long control
region (LCR) of HPV16, HPV18 and HPV51. HPV genomes were analyzed using bisulﬁte DNA modiﬁcation
procedure with the subsequent ampliﬁcation of target DNA regions and sequencing. A collection of 202
cervical specimens was analyzed: 157 HPV16-positive specimens, 21 HPV18-positive specimens and 24
HPV51-positive specimens. This study revealed that methylation of CpG was signiﬁcantly more prevalent
in L1 gene as compared to LCR region of all three studied HPV types and the degree of DNA methylation
level correlated with the severity of cervical neoplasia. An increased DNA methylation level of HPV16
promoter region in case of cervical cancer was determined.
& 2015 Elsevier Inc. All rights reserved.
Introduction
Human papilllomaviruses (HPVs) are common human patho-
gens that infect cutaneous or mucosal epithelia in which they may
cause benign and cancer diseases. The development of cervical
neoplasia is linked to the infection with at least one of 13 high-risk
HPV types (HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68)
(Cogliano et al., 2005). Epidemiologic and molecular studies
revealed that persistent infections with high-risk types of HPV
are essential in the pathogenesis of cervical carcinoma but addi-
tional genetic and epigenetic alterations are required for triggering
the carcinogenesis (Lazo, 1999).
Epigenetic regulation of gene expression is mediated by highly
speciﬁc DNA methylation and histone modiﬁcation patterns. DNA
methylation is one of the most studied epigenetic modiﬁcations,
which occurs at the cytosine bases of CpG sequences. During this
process, cytosine bases are converted to 5-methylcytosine by DNA
methyltransferase. Methylated cytosines have an important
impact on gene expression by either physical blocking of binding
sites of transcriptional proteins involved in gene expression
processes or by changing chromatin structures responsible for
inhibiting transcription. Previous studies have revealed an impor-
tant role of DNA methylation in the transcriptional regulation of
speciﬁc genes and causal relationship between certain defects in
DNA modiﬁcation mechanisms and various diseases including
cancer (Kulis and Esteller, 2010).
HPV long control region (LCR) contains viral promoter
sequences of early genes including viral oncogenes E6 and E7,
viral transcriptional enhancer and viral origin of DNA replication
(Burd, 2003). DNA methylation of HPV LCR is one of possible
mechanisms by which transcription of E6 and E7 genes are
regulated. DNA methylation studies indicated that the degree of
CpG methylation at HPV16 LCR sequences increased with the
severity of the disease (Ding et al., 2009; Hong et al., 2008;
Kalantari et al., 2004). HPV16 DNA sequences are found in
carcinoma cells most often integrated into the host genome and
in some cases integration of multiple HPV copies can occur as
tandem repeats that represent efﬁcient DNA methylation targets
(Daniel et al., 1995). Such methylation of HPV LCR DNA sequences
may serve as a host defense mechanism for silencing the tran-
scription and replication of viral genomes. However, a certain
degree of LCR DNA methylation was also detected in asymptomatic
patients (Ding et al., 2009; Hong et al., 2008; Kalantari et al.,
2004). In contrast to HPV16, a few previous studies have shown
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that LCR DNA sequences of HPV18 were unmethylated in DNA
samples extracted from specimens with different degrees of
cervical pathologies (Turan et al., 2006; Badal et al., 2004).
The 30 parts of HPV L1 genes located upstream of LCR have been
also investigated as targets for DNA methylation. Investigation of
DNA samples puriﬁed from cervical cancer specimens has shown
that L1 genes of HPV16 and HPV18 are methylated and the degree
of DNA methylation of target sequences increases correspondingly
to the severity of the disease (Kalantari et al., 2004; Turan et al.,
2006; Badal et al., 2004; Bryant et al., 2014). DNA methylation
pattern of L1 gene sequences of various HPV types provides a basis
for speculations that methylation of HPV L1 genes might be a
result of HPV integration into the host DNA (Kalantari et al., 2004,
2008, 2010; Bryant et al., 2014; Van Tine et al., 2004).
DNA methylation frequencies of other high-risk HPV types such
as HPV31, HPV33, HPV45, HPV52 and HPV58 have been investi-
gated to a lesser extent as compared to HPV16 and HPV18. There
are no experimental data on DNA methylation pattern of other
high-risk HPV types such as HPV35, HPV39, HPV51, HPV56, HPV59
and HPV68 (Murakami et al., 2013; Vasiljevic et al., 2014;
Wentzensen et al., 2012). It is still not known how HPV DNA
sequences are recognized by cellular DNA methyltransferases and
what is the impact of DNA methylation on HPV life cycle and the
carcinogenesis process. Therefore, further HPV DNA methylation
studies are important for better understanding of HPV-induced
carcinogenesis.
The aim of the current study was to investigate the methylation
pattern of selected DNA sequences of three high-risk HPV types –
HPV16, HPV18 and HPV51 isolated from clinical specimens with
different grades of cervical pathology and to evaluate possible
correlations between HPV DNA methylation levels and the severity
of cervical neoplasia. For the ﬁrst time, methylation pattern of
HPV51 DNA isolated from clinical specimens has been analyzed.
Results
Study design
DNA bisulﬁte modiﬁcation and sequencing of target amplicons
were used to determine the CpG methylation status of HPV16,
HPV18 and HPV51 genomes at 30 part of L1 gene and LCR
sequences in DNA samples puriﬁed from a collection of cervical
specimens with conﬁrmed HPV infection (n¼202). Complete
conversion of cytosines into thymidines in all non-CpG sites of
the analyzed DNA sequences after bisulﬁte treatment was proven
by DNA sequencing that conﬁrmed a successful modiﬁcation of all
DNA samples. The degree of HPV DNA methylation was evaluated
as a percentage of methylated CpG sites along the selected parts of
HPV genomes (30 part of the L1 gene and the LCR region)
calculated in the subgroups with identiﬁed cervical pathology.
HPV DNA sequences were scored as methylated case if at least one
CpG site of the region selected for investigation was methylated.
DNA samples puriﬁed from CaSki and HeLa cell lines were used as
positive controls for HPV16 DNA and HPV18 DNA, respectively. All
HPV DNA amplicons were sequenced in both directions seeking
the most efﬁcient determination of the methylated CpG sites.
Sequencing data of analyzed PCR products sometimes showed the
presence of overlapping C and T peaks in the same position,
indicating heterogenic methylation of CpG dinucleotides in the
population of the studied HPV DNA molecules.
Methylation of HPV16 DNA target sequences
Methylation status of 17 CpG dinucleotides of the selected
HPV16 DNA sequences was investigated in 157 DNA samples
isolated from HPV16-infected cervical specimens. Two of these
17 CpG dinucleotides were located in 30 part of the L1 gene
(positions from 7136 nt to 7145 nt of HPV genome), 4 CpG
dinucleotides were located in LCR 50 segment sequences (positions
from 7270 nt to 7461 nt), 6 CpG dinucleotides were located in DNA
region encoding the transcriptional enhancer (positions from 7535
nt to 7862 nt) and 5 pairs of CpG were located in E6 promoter
sequences (positions from 31 nt up to 58 nt) (Table 2). Investiga-
tions of DNA methylation frequency at selected CpG dinucleotides
revealed high variability in cytosine methylation among selected
CpG sites and among different amplicons. Investigation of HPV16
DNA methylation pattern revealed a strong correlation between
the increased CpG methylation of selected DNA sequences and the
severity of cervical neoplasia. In general, the methylation of CpG
sequences was more prevalent in L1 gene and promoter region
sequences as compared to LCR 50 and enhancer regions of HVP16
DNA. The degree of DNA methylation of at least one CpG
dinucleotide of HPV16 L1 gene ranged from 0% in a subgroup of
CIN I up to 35.5% in a subgroup of cervical cancer. In a similar way,
the degree of CpG methylation within the sequences of HPV16
DNA promoter region ranged from 0% in CIN I up to 32.3% in
cervical cancer. Methylation frequency of CpG dinucleotides in
HPV16 DNA sequences of LCR 50 and enhancer regions ranged from
0% in CIN I up to 25.8% in cervical cancer. In addition, we detected
6.9% methylated CpG dinucleotides within the selected HPV16
DNA sequences in case of asymptomatic HPV16 infections in
comparison to 22.6% methylated CpG within the same HPV16
DNA sequences in cervical cancer. Statistically signiﬁcant differ-
ence after Bonferroni correction was detected between HPV16
DNA methylation frequency within the selected sequences of L1
gene in asymptomatic HPV16 infection as compared to cervical
cancer (P¼0.0027, Table 3).
DNA methylation frequency of the individual CpG sites within
the selected sequences of DNA ranged from 0% in asymptomatic
HPV16 infection up to 11.8% in CIN I/II. Even more differences in
HPV16 DNA methylation pattern were detected in amplicons
generated from DNA samples isolated from specimens with CIN
III/CIS and cervical cancer specimens: the degree of HPV16 DNA
methylation ranged from 0% up to 35.5%, respectively. The highest
frequency of HPV16 DNA methylation (35.5%) was detected
at positions of 7136 nt and 7145 nt of DNA sequences generated
from cervical cancer specimens. Statistically signiﬁcant DNA
Table 1
PCR primers used for ampliﬁcation of bisulﬁte-modiﬁed HPV16, HPV18 and HPV51
DNA sequences.
Primer Position in HPV
genome (nt)
Sequence, 50–30
16msp3F 7049–7078 AAGTAGGATTGAAGGTTAAATTAAAATTTA
16msp3R 7590–7560 AACAAACAATACAAATCAAAAAAACAAAAA
16msp4F 7465–7493 TATGTTTTTTGGTATAAAATGTGTTTTT
16msp4R 7732–7703 TAAATTAATTAAAACAAACCAAAAATATAT
16msp5F 7748–7777 TAAGGTTTAAATTTTTAAGGTTAATTAAAT
16msp5R 115–86 ATCCTAAAACATTACAATTCTCTTTTAATA
18msp6F 6847–6871 TTATTAGTTTGGTGGATATATATTG
18msp6R 7186–7161 AAAACATACAAACACAACAATAAATA
18msp10F 7282–7293 TAAAATATGTTTTGTGGTTTTGTG
18msp10R 7747–7721 ATAATTATACAAACCAAATATACAAT
18msp8F 7753–7781 TGTTTAATATTTTGTTTATTTTTAATATG
18msp8R 186–161 TATCTTACAATAAAATATTCAATTCC
51msp1F 6848–6874 AATATAAATTTTGGGATGTTGATTTAA
51msp1R 7064–7038 ATTCACAAACATACAAAAACTAACATA
51msp2F 7139–7165 TGTATGTATGAGTTATGTATGTTTATT
51msp2R 7354–7326 ACTACAAAATATAACTAAATAACACAAAT
51msp3F 7325–7353 TATTTGTGTTATTTAGTTATATTTTGTAG
51msp3R 7639–7553 ATACCAAAAAATACATACCTATAAACA
51msp4F 7668–7696 AGGTTAAATATTATGTTTTTAGTGTTAA
51msp4R 99–72 CATAATATTCAACTATACTTTTACCACT
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methylation differences after Bonferroni correction were deter-
mined at positions of 7136 nt and 7145 nt between DNA samples
isolated from cervical specimens with asymptomatic HPV16 infec-
tion as compared to cervical cancer specimens (P¼0.0027 and
P¼0.0003, respectively). The degree of HPV16 DNA methylation
was low at CpG dinucleotides located at four positions: 7270 nt,
7535 nt, 7695 nt and 7862 nt among all investigated specimens.
The frequency of DNA methylation at 7270 nt, 7535 nt and 7695 nt
positions ranged from 0% in asymptomatic HPV16 infection up to
6.5% in cervical cancer. Noteworthy, the cytosines located at 7862
nt position were unmethylated in all studied cervical specimens. In
contrast to HPV16 DNA sequences obtained from clinical speci-
mens, DNA puriﬁed from HPV16-transformed CaSki cell line used
as a positive control demonstrated complete methylation of all
cytosines in all CpG sites along the selected DNA sequences. HPV16
DNA methylation frequency at all other analyzed CpG sites ranged
from 0% up to 32.3% in different subgroups but none of them were
proven to be statistically signiﬁcant (Fig. 1; Supplementary
Table 4).
Methylation of HPV18 DNA target sequences
The frequency of HPV18 DNA methylation was evaluated at 25
CpG dinucleotides along the selected sequences obtained from
bisulﬁte-modiﬁed and ampliﬁed DNA isolated from HPV18-
positive cervical specimens (n¼21). Ten of the selected 25 CpG
sites were located in 30 part of the L1 gene (positions from 6916 nt
to 7122 nt), 1 CpG site was located in LCR 50 segment sequence
(position 7316 nt), 8 CpG dinucleotides were distributed along the
sequence recognized by the transcriptional enhancer (positions
from 7460 nt to 7631 nt), and 6 CpG sites were located in E6
promoter sequence (positions from 7824 nt to 66 nt) (Table 2).
An extremely high frequency of HPV18 DNA methylation was
detected in L1 30 region sequences of the subgroups diagnosed
with CIN III/CIS and cervical cancer. The degree of HPV18 DNA
methylation at positions from 6916 nt to 7122 nt (10 CpG
dinucleotides in a part of L1 30 region) reached 100% in DNA
samples obtained from subgroups of cervical cancer and CIN III/
CIS. Only one HPV18 DNA sample in the subgroups of asympto-
matic HPV18 infections and CIN I was methylated within the 30
part of L1 gene. In contrast to this unique HPV18 DNA sample, no
one HPV18 DNA sample from a subgroup of CIN II was methylated
along the 30 part of L1 gene. Only one HPV18 DNA sample isolated
from the subgroup of CIN III/CIS and only 2 HPV18 DNA samples
puriﬁed from cervical cancer specimens were found to be methy-
lated along the LCR 50 region sequences at 7316 nt. HPV18 DNA
enhancer and promoter region sequences were methylated at
positions from 7460 nt to 66 nt only in one DNA sample
representing the subgroup of cervical cancer. Similarly to HPV16,
unmethylated cytosines were identiﬁed at positions 7824 nt and
50 nt in all analyzed HPV18 DNA samples. In contrast to clinical
specimens, the selected DNA sequences of HPV18-transformed
HeLa cells used as a positive control were methylated at all CpG
dinucleotides along the selected L1 gene and LCR 50 part
sequences. No methylated cytosines were detected within other
selected parts of DNA isolated from cervical specimens with
HPV18 infection. In summary no statistically signiﬁcant differences
of HPV18 DNA methylation frequency at all selected CpG positions
(from 6916 nt to 66 nt) were determined when HPV18 DNA
Table 2
The positions of CpG sites in the L1 30 , LCR 50 , enhancer and promoter regions of HPV16, HPV18 and HPV51.
HPV DNA HPV16 HPV18 HPV51
Region CpG, nt CpG, nt CpG, nt
L1 30 7136, 7145 6916, 7011, 7038, 7041, 7062, 6916, 6939, 6946, 6970,
7068, 7090, 7110, 7116, 7122 6974, 6983, 7015, 7021
LCR 50 7270, 7428, 7455, 7461 7316 7228, 7256, 7277, 7283
Enhancer 7535, 7554, 7677, 7460, 7466, 7511, 7573, 7393, 7399, 7404, 7498, 7502, 7508
7683, 7695, 7862 7575, 7586, 7597, 7631 7522, 7524, 7532, 7535, 7594
Promoter 31, 37, 43, 52, 58 7824, 44, 50, 54, 60, 66 7762, 32, 48, 54
Table 3
HPV16 (A), HPV18 (B) and HPV51 (C) DNA methylation frequency within the L1 30
and LCR 50 regions.
A
Group L1 30 LCR 50 Enhancer Promoter
No. % No. % No. % No. %
CIN I (n¼10) 0 0 0 0 1 10 0 0
CIN II (n¼17) 1 5.9 2 11.8 3 17.6 2 11.8
CIN III/CIS (n¼70) 17 24.3 10 14.3 16 22.9 18 25.7
CC (n¼31) 11 35.5* 8 25.8 7 22.6 10 32.3
Normal (n¼29) 1 3.4* 1 3.4 2 6.9 1 3.4
B
Group L1 30 LCR 50 Enhancer Promoter
No. % No. % No. % No. %
CIN I (n¼3) 1 33.3 0 0 0 0 0 0
CIN II (n¼2) 0 0 0 0 0 0 0 0
CIN III/CIS (n¼2) 2 100 1 50 0 0 0 0
CC (n¼6) 6 100 2 33.3 1 16.7 1 16.7
Normal (n¼8) 1 12.5 0 0 0 0 0 0
C
Group L1 30 LCR 50 Enhancer Promoter
No. % No. % No. % No. %
CIN I (n¼6) 0 0 0 0 0 0 0 0
CIN II (n¼4) 0 0 0 0 0 0 0 0
CIN III/CIS (n¼5) 0 0 0 0 0 0 0 0
CC (n¼1) 1 100 0 0 0 0 0 0
Normal (n¼9) 0 0 0 0 0 0 0 0
CIN I, cervical intraepithelial neoplasia grade 1; CIN II, cervical intraepithelial
neoplasia grade 2; CIN III/CIS, cervical intraepithelial neoplasia grade 3 or carci-
noma in situ; CC, cervical cancer; Normal, asymptomatic HPV infection.
n P¼0.0027
Fig. 1. Distribution of the methylated CpG sites along the selected sequences of
DNA isolated from HPV16-positive specimens with different degrees of cervical
pathology: CIN I, cervical intraepithelial neoplasia grade 1; CIN II, cervical
intraepithelial neoplasia grade 2; CIN III/CIS, cervical intraepithelial neoplasia grade
3 or carcinoma in situ; CC, cervical cancer conﬁrmed by histology; Normal,
asymptomatic HPV infection.
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samples isolated from specimens with different grades of cervical
pathology were compared (Fig. 2; Supplementary Table 4).
DNA methylation of HPV51 DNA target sequences
HPV51 DNA methylation pattern at 27 selected CpG sites were
investigated using 24 DNA samples puriﬁed from cervical speci-
mens infected with HPV51. Eight of these 27 CpG sites were
located within the 30 part of L1 gene sequence from 6916 nt to
7021 nt, 4 CpG dinucleotides were selected from LCR 50 segment
sequence from 7228 nt to 7283 nt, 11 CpG sites were selected
within the sequence recognized by the transcriptional enhancer
(from 7393 nt to 7594 nt) and 4 CpG sites were selected from the
sequence of E6 promoter (from 7762 nt to 54 nt) (Table 2).
Unexpected pattern of HPV51 DNA methylation was detected in
almost all DNA samples puriﬁed from 24 HPV51-positive cervical
specimens: DNA sequences were unmethylated along all ampli-
cons selected for detailed analysis. The exception was detected
only in one HPV51 DNA sample representing the subgroup of
cervical cancer: in this specimen all cytosines were methylated
within the 30 part of L1 gene sequences from 6916 nt to 7021 nt.
Data on HPV51 DNA methylation frequency along the selected
target sequences are presented in Table 3.
Discussion
HPV infection is the most common viral infection of the
reproductive tract that may cause cervical cancer and precancer-
ous pathology (Longworth and Laimins, 2004; Hoory et al., 2008).
According to the World Health Organization, cervical cancer is the
second most common cancer in women worldwide. Every year,
530,000 new cases of cervical cancer are reported and more than
270,000 women die from cervical cancer (World Health
Organisation, 2014). Therefore it is important to investigate the
mechanisms of carcinogenic progression induced by HPV16,
HPV18 and other high-risk HPV types.
In the current study, DNA methylation status of HPV16, HPV18
and HPV51 genomes representing the selected sequences encom-
passing CpG dinucleotides within the 30 part of L1 gene and LCR
region sequences were investigated in clinical specimens with
conﬁrmed HPV infection and different grades of cervical pathol-
ogy. To our knowledge, this is the ﬁrst study to investigate the DNA
methylation pattern of HPV51. The obtained data revealed that
DNA methylation of 30 part of HPV L1 gene is much more prevalent
than that of viral LCR. Moreover, HPV DNA methylation frequency
is much higher in DNA samples isolated from carcinoma speci-
mens than in those isolated from cervical specimens with asymp-
tomatic HPV infection. The highest degree of HPV16 DNA
methylation (35.5%) was determined along the 30 part of the L1
gene in case of cervical cancer. The lowest HPV DNA methylation
frequency was detected in the selected DNA sequences of the
subgroups of CIN I (0%) and asymptomatic HPV16 infection (3.4%).
Similar pattern of HPV16 DNA methylation was detected within
the promoter region sequences. The degree of DNA methylation
ranged from 0% in HPV16 DNA samples representing CIN I to 32.3%
in HPV16 DNA samples representing cervical cancer. Statistically
signiﬁcant differences in HPV16 DNA methylation of L1 region
sequences were detected between the subgroups of asymptomatic
HPV16 infection and cervical cancer (P¼0.0027). Lower HPV16
DNA methylation frequency (ranging from 0% to 25.7%) were
determined within other LCR regions (Fig. 1, Supplementary
Table 4). Previous studies on HPV16 DNA methylation reported
similar positive relationship between the degree of methylation in
the L1 gene and the severity of cervical pathology (Kalantari et al.,
2009; Fernandez et al., 2009; Brandsma et al., 2009; Sun et al.,
2011; Mirabello et al., 2012). However, previous data on the
association between HPV DNA methylation in the LCR region and
the grade of cervical pathology are rather controversial. Several
studies have revealed a decreased DNA methylation frequency in
viral LCR region sequences generated from DNA samples isolated
from HPV-infected specimens with cervical pathology (Ding et al.,
2009; Badal et al., 2003; Xi et al., 2011; Mazumder et al., 2011;
Snellenberg et al., 2012; Vinokurova and von Knebel, 2011;
Bhattacharjee and Sengupta, 2006). Despite these controversial
results on the pattern of HPV DNA methylation in cervical
pathology, several ﬁndings are common: in most previous studies
the level of DNA methylation at 7862 nt (CpG) in the enhancer
region was found to be very low. In line with these data, in the
current study all analyzed HPV DNA samples were found to be
unmethylated at position 7862 nt. The indicated CpG position
(7862 nt) overlaps with E2 binding site. It is well-documented that
E2 gene products repress the transcription of oncogenes E6 and E7.
Therefore, the methylation of E2 binding site might lead to the loss
of E2 repression and sustained E6/E7 expression (Ding et al., 2009;
Kalantari et al., 2004; Vinokurova and von Knebel, 2011;
Bhattacharjee and Sengupta, 2006). In line with many previous
studies, the current research has demonstrated that HPV16 DNA
methylation within the viral promoter region is increased in case
of cervical cancer as compared to other types of cervical pathology
or asymptomatic HPV infection. (Ding et al., 2009; Hong et al.,
2008; Badal et al., 2003; Xi et al., 2011; Snellenberg et al., 2012;
Fig. 2. Distribution of the methylated CpG sites along the selected sequences of DNA isolated from HPV18-positive specimens with different degrees of cervical pathology:
CIN I, cervical intraepithelial neoplasia grade 1; CIN II, cervical intraepithelial neoplasia grade 2; CIN III/CIS, cervical intraepithelial neoplasia grade 3 or carcinoma in situ; CC,
cervical cancer conﬁrmed by histology; Normal, asymptomatic HPV infection.
V. Simanaviciene et al. / Virology 484 (2015) 227–233230
Bhattacharjee and Sengupta, 2006; Piyathilake et al., 2011). HPV
DNA promoter sequences contain two E2 binding sites, therefore if
the sequences undergo modiﬁcation by DNA methylation, the
binding of transcriptional repressor E2 to these sites may be
blocked thus promoting expression of E6 and E7 oncogenes
(Thain et al., 1996). It has been discussed in previous reports that
HPV DNA methylation within that speciﬁc HPV region may serve
as a biomarker of carcinogenic progression (Bhattacharjee and
Sengupta, 2006). It is also important to note that the LCR DNA
sequences of low-risk HPV6 and HPV11 types are completely
unmethylated (Ure and Forslund, 2012; Gall et al., 2011).
The current study also revealed the highest methylation fre-
quency of HPV18 DNA along the 30 part of L1 gene sequences. DNA
methylation frequency reached 100% in the selected sequences of
HPV DNA isolated from specimens with CIN III/CIS and cervical
cancer. In contrast, DNA methylation levels at the selected sequences
of HPV18 LCR were low among all tested cervical HPV DNA samples
(Fig. 2; Supplementary Table 4). The obtained data on the pattern of
HPV18 DNA methylation are in a full concordance to previous
reports, demonstrating an intense (often exceeding 80%) methylation
at CpG positions within the 30 part of L1 gene sequences in DNA
samples isolated from cervical cancer specimens, and very low
methylation (often none), in the HPV18 LCR DNA sequences (Turan
et al., 2006; Badal et al., 2004; Fernandez et al., 2009).
For the ﬁrst time, DNA methylation pattern of the selected parts
of HPV51 genome was analyzed in DNA samples puriﬁed from
cervical specimens with a various grade of cervical pathology. This
collection of HPV51-positive specimens included only 1 case of
cervical cancer. Noteworthy, we detected methylated cytosines
within the 30 part of L1 gene sequences (from 6916 nt to 7021 nt)
only in this single HPV51 DNA sample representing a case of
cervical cancer (Table 3). The obtained data are in line with data on
HPV16 and HPV18 DNA methylation at the same locus. All other
analyzed HPV51 DNA sequences were found to be unmethylated in
all tested samples representing the subgroups of asymptomatic
HPV51 infection, CIN I/II and CIN III/CIS. Methylation pattern of
other high-risk HPV types, such as HPV31, HPV33, HPV45, HPV52
and HPV58 have been analyzed in recent studies. Obtained data
demonstrated that HPV DNA methylation frequency of the L1 gene
is much more prevalent than that of the LCR sequences and
correlates with the severity of cervical pathology (Murakami et
al., 2013; Vasiljevic et al., 2014; Wentzensen et al., 2012). However,
the biological basis for the association between HPV L1 gene
methylation and cervical cancer progression is still unclear. A
few studies showed that the L1 gene methylation is associated
with HPV integration into cellular DNA (Kalantari et al., 2004,
2008; Bryant et al., 2014; Van Tine et al., 2004). Although DNA
methylation represents gene repression mechanism, the product
of L1 gene is HPV capsid protein not involved into carcinogenesis
processes. HPV DNA methylation events can be interpreted as a
host defense mechanism based on methylation of chromosomally
integrated foreign DNA (retroviruses, transgenes, transfected ade-
novirus genomes) (Doerﬂer et al., 2001; Sutter and Doerﬂer, 1980).
For example, HPV16-positive cells line CaSki contains HPV16
genomes in a form of integrated tandem repeats that represent
efﬁcient targets for DNA methylation. However, integration of
HPV16 genomes does not mean that cancer cells do not have
transcriptionaly active HPV DNA sequences. In contrary, some of
these genomes remain unmethylated and therefore a productive
HPV infection is maintained (Badal et al., 2003).
Conclusions
The current study presents new data on DNA methylation
pattern at 30 parts of the L1 gene and the LCR sequence of
HPV16, HPV18 and HPV51. For the ﬁrst time, DNA methylation of
HPV51 was investigated. The methylation of cytosines in CpG sites
was more prevalent in the L1 gene than in the LCR sequence of all
analyzed HPV DNA samples. Moreover, the frequency of HPV DNA
methylation correlated with the severity of cervical neoplasia. The
current study also revealed an increased DNA methylation level of
HPV16 promoter region in case of cervical cancer as compared to
other types of cervical pathology and asymptomatic HPV16 infec-
tion. The identiﬁed epigenetic alterations in high-risk HPV gen-
omes may serve as a potential biomarker for HPV-induced
carcinogenesis.
Materials and methods
Materials
Maxima™ Hot Start PCR buffer, Hot Start Taq DNA polymerase,
2 mM dNTP, 25 mMMgCl2, agarose, BSA, O'GeneRuler™ 50 bp DNA
Ladder, “GeneJet™ Genomic DNA Puriﬁcation Kit”, “GeneJET Gel
Extraction and DNA Cleanup Micro Kit” were purchased from
Thermo Fisher Scientiﬁc Baltics UAB (Vilnius, Lithuania). “DNA
Methylation-Gold Kit” was obtained from Zymo Research (Irvine,
CA, USA). All oligonucleotides were obtained from Metabion
(Steinkirchen, Germany). Cervical cell lines used in the study:
CaSki (60–600 copies of HPV16 per genome) and HeLa (10–50
copies of HPV18 per genome) were obtained from American Type
Culture Collection (Manassas, VA).
Clinical specimens and study groups
In total, 824 women (aged from 18 to 80 years) with known
histological and/or cytological diagnosis were included into the
study. Cervical samples were collected from the cervix using
cervical brush during our previous study on the prevalence of
oncogenic HPV types among Lithuanian women with cervical
pathology (Simanaviciene et al., 2015). The study was approved
by Vilnius Regional Committee of Biomedical Research (Lithuania,
permission no. 158200-6-062–16, 2009-06-03). In total, 202 clin-
ical specimens with known histological diagnosis were included
into the study: 157 HPV16-positive clinical specimens, 21 HPV18-
positive clinical specimens and 24 HPV51-positive clinical speci-
mens. HPV16-positive clinical specimens (n¼157) consisted of 10
cases of grade 1 cervical intraepithelial neoplasia (CIN I), 17 cases
of grade 2 cervical intraepithelial neoplasia (CIN II), 70 cases of
grade 3 cervical intraepithelial neoplasia or carcinoma in situ (CIN
III/CIS), 31 cases of cervical cancer and 29 cases of asymptomatic
HPV16 infection. HPV18- positive clinical specimens (n¼21)
included 3 cases of CIN I, 2 cases of CIN II, 2 cases of CIN III/CIS,
6 cases of cervical cancer and 8 cases of asymptomatic HPV18
infection. HPV51-positive specimens (n¼24) consisted of 6 cases
of CIN I, 4 cases of CIN II, 5 cases of CIN III/CIS, 1 case of cervical
cancer and 8 cases of asymptomatic HPV51 infection.
DNA puriﬁcation
DNA samples from cell lines HeLa (ATCC NO. CCL-2) and Caski
(ATCC NO. CRL-1550) were puriﬁed using “GeneJET™ Genomic
DNA Puriﬁcation Kit” according to manufacturer's instruction.
Detailed description of collected cervical specimens and the
procedure of DNA extraction from cervical specimens have been
presented previously (Simanaviciene et al., 2015).
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Bisulﬁte DNA modiﬁcation, PCR and DNA sequencing
DNA extracted from cervical specimens was used for bisulﬁte
modiﬁcation using “DNA Methylation-Gold Kit” according to
manufacturer's instructions. DNA samples were stored at 20 1C
until use. Bisulﬁte DNA modiﬁcation may cause DNA fragmenta-
tion, therefore ampliﬁcation of large genomic DNA segments is
limited in most cases by speciﬁc features of procedure used for
bisulﬁte DNA treatment. Taking it into account, target HPV DNA
sequences selected for methylation analysis were split into 3–4
genomic segments. Three sets of primer pairs were used to
amplify bisulﬁte-modiﬁed HPV16 DNA sequences containing 30
part of L1 gene and LCR sequences (Kalantari et al., 2004).
Modiﬁed DNA samples were ampliﬁed in the form of 3 separate
amplicons located at the following positions of viral genome:
7049–7590 nucleotides (nt), 7465–7732 nt and 7748–115 nt.
According to the same order, 3 sets of primer pairs were used to
amplify HPV18 DNA sequences of 30 part of the L1 gene and the
LCR (Badal et al., 2004). Three target sequences for generation of
amplicons from DNA samples of HPV18-infected specimens were
located at the following positions of viral genome: 6847–7186 nt,
72829–7747 nt and 7753–186 nt. Other 4 sets of primer pairs were
designed to amplify HPV51 DNA sequences containing 30 part of
the L1 gene and LCR, using the MethPrimer Design program
(http://www.urogene.org/methprimer/). The beginnings and the
ends of 4 amplicons of HPV51 bisulﬁte-modiﬁed DNA were
selected at the following positions of viral genome: 6848–7064
nt, 7139–7354 nt, 7325–7639 nt and 7668–99 nt. Table 1 sum-
marizes all sets of primers used for speciﬁc ampliﬁcation of
HPV16, HPV18 and HPV51 bisulﬁte-modiﬁed DNA samples. All
PCR procedures were performed in a ﬁnal volume of 25 ml with the
following composition: 22 ml of Master Mix (consisted of Hot Start
PCR buffer, MgCl2, Hot Start Taq DNA polymerase, dNTP, BSA,
primer pair, and water) and 3 ml of bisulﬁte-modiﬁed DNA. PCR
was run according to the following protocol: 94 1C for 5 min, 40
cycles at: 94 1C 10 s, 54 1C 30 s, 68 1C 1 min, and a ﬁnal extension
at 68 1C for 7 min. Obtained PCR products were analyzed in
ethidium bromide-stained agarose gels and sequenced directly
using reagent kit BigDye Terminator v3.1 Cycle Sequencing Kit and
Applied Biosystems 3730 l DNA Analyzer (Baseclear, Leiden, The
Netherlands).
Statistical analysis
All HPV DNA methylation data were analyzed using Microsoft
Excel and Statistica 8 programs. The frequency of methylation of
CpG sites between different groups of investigated HPV DNA
specimens were compared using Fisher's exact test. In total, 17
CpG positions of HPV16, 25 CpG positions of HPV18 and 27 CpG
positions of HPV51 were analyzed in the corresponding HPV DNA
sequences. A high number of statistical comparisons were per-
formed, therefore we adjusted the level of signiﬁcance for the
statistical tests by using Bonferroni's adjustment for multiple
comparisons.
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